Seattle-based Presage Biosciences, a spinoff from the Fred Hutchinson Cancer Research Center, has raised $1.6 million out of a new equity financing that could be worth as much as $10.5 over time, according to a regulatory filing. The document doesn’t say who is backing the company, although it says the round includes 20 investors. Presage, which has previously raised at least $4 million, has developed a tool that drugmakers are using to get a better sense of which experimental drugs are likely to succeed in clinical trials.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
